PriMera Scientific Medicine and Public Health (ISSN: 2833-5627)

Thesis

Volume 6 Issue 6

Direct non-medical costs of breast cancer treatment at the Joliot Curie Institute of Aristide Le Dantec Hospital in Dakar, Senegal

Mory DIALLO*, Dieynaba FALL and Jean Birane GNING

June 04, 2025

View PDF

Abstract

Introduction: In 2022, the incidence of breast cancer amounted to 2,296,840 cases worldwide, including 198,553 in Africa and 1,838 cases in Senegal. However, the direct non-medical costs of treating cancer in general are not known in Senegal. For a better allocation of resources, it is important to estimate their costs. The objective of this article is to analyze the direct non-medical costs of breast cancer treatment at the Joliot Curie Institute in Dakar.

Methods: This is a retrospective study conducted on patients diagnosed with breast cancer between January and December 2017 at the Joliot Curie Institute. A questionnaire survey and semi-structured interviews were conducted with sick people and their relatives to reconstruct the direct non-medical cost.

Results: The estimated average direct non-medical cost of breast cancer treatment at Joliot Curie Institute is 2,844,731 FCFA ($4,559.79) with a minimum of 359,650 FCFA ($576.48) and a maximum of 7,110,584 FCFA ($11,397.48) over an average duration of 31 months. In addition, the analysis of this average direct non-medical cost reveals that it is made up of 63.45% of the cost of housing; 22.48% of the cost of food and 12.27% of the cost of transportation. The reduction of sequelae related to treatment constitutes only 1.8%.

Conclusion: The direct non-medical cost of breast cancer treatment is very high in Senegal. The non-medical direct cost of the maximum treatment is 7,110,584 FCFA ($11,397.48) and the minimum is 359,650 FCFA ($576.48), i.e. an average cost of 2,844,731 FCFA ($4,559.79)1.

Keywords: Direct non-medical costs; breast cancer; breast cancer treatment; Joliot Curie Institute; Senegal

References

  1. Abolhasan Afkar., et al. “Breast Cancer Cost Analysis: A Comparison Between Private and Public Hospitals in Iran”. BMC Health Services Research (2021).
  2. Adanu KK., et al. “Cost of home breast cancer treatment and cost adjustment strategies of a tertiary facility in Ghana”. PLOS Clob public Health (2022).
  3. Astrid Nathalia Páez Esteban., et al. “Direct and indirect costs derived from the family care of patients with chronic non-communicable diseases”. Aquichan (2020).
  4. Bapna Ajay PS. “A retrospective analysis of the hormone receptor profile in breast cancer patients from a tertiary cancer center in western India and investigates their relationship with its 2 Neu (IHC + FISH), age, and menopausal states”. Prensa Med Argent 105.2 (2019).
  5. Baudouin KK., et al “Epidemiological, clinical and diagnostic profile of breast cancer patients treated at the Potchefstroom Regional Hospital, South Africa from 2012-2018: an open-label cohort study”. Pan african Medical Journal 36.9 (2020).
  6. Carlson Babila Sama BD. “Breast cancer awareness and breast self-examination among undergraduate students at a higher normal school in Cameroon”. Panafrican Medical Journal 28.91 (2017): 28-91.
  7. IARC. Report on the International Cancer Observatory (2022).
  8. Croyle R. Cancer Trends Progress Report. (National Cancer Institute) (2021).
  9. Delphine Héquet., et al. “Direct medical and non-medical costs of a one-year care pathway for early operable breast cancer: Results of a French multicenter prospective study”. PLoS One (2019).
  10. Dinah A Tetteh and Sandra L Faulkner. “Sociocultural factors and breast cancer in sub-Saharan Africa: Implications for diagnosis and management”. Sage journals 12.1 (2016): 147-156.
  11. Eric Osei., et al. “Perceived risk of breast cancer among female undergraduates in Ghana: A cross-sectional study”. Journal of Oncology (2021): 8811353.
  12. Felicia KM., et al. “The health care costs of breast cancer: the case of the Mexican Social Security Institute”. Salud Publica Mex (2009): 286-295.
  13. Gonzaga AM. “Listening to Voices: An exploratory study of the experiences of women diagnosed with and living with breast cancer in Uganda”. Panafrican Medical Journal 16 (2013).
  14. Gulia Seema., et al. “Evaluation of 1 year versus shorter durations of adjuvant trastuzumab in patients with early breast cancer: Data from an individual participant and trial-level meta-analysis”. JAMA Netw 3.8 (2020).
  15. Gupta Nidhi., et al. “Cost-effectiveness of trastuzumab for breast cancer management in India”. JCO Glob Oncol 6.1 (2020): 205-216.
  16. Hamraz Mokri., et al. “Future medical and non-medical costs and their impact on the cost-effectiveness of life extension interventions: a comparison of five European countries”. The European Journal of Health Economics (2022).
  17. Hierrhum Aboubacar Bambara., et al. “Breast cancer: descriptive profile of 80 women attending breast cancer care in the general and digestive surgery department of the CHU-YO”. Panafrican Medical Journal 28.314 (2017): 28-314.
  18. Hughes GA., et al. “Economic Cost of Breast Cancer in Ghana: The Experience of Komfo Teaching Hospital”. Journal of Business Research (2012).
  19. Jacobo Gómez-Rico., et al. “The costs of breast cancer in a Mexican public health institution”. Dove Medical Press 2008.1 (2008): 15-21.
  20. Janz NK., et al. “Population-based study of the relationship between treatment and sociodemographics on the quality of life of early-stage breast cancer”. Research on the quality of life (2005): 1465-1479.
  21. Julius Gbenga Olaogun., et al. “Sociodemographic, model of presentation and outcome of breast cancer management in a semi-urban tertiary health facility”. Panafrican Medical Journal 36.363 (2020).
  22. K Xu., et al. “Catastrophic household health expenditures: a multi-country analysis”. The Lancet (2003): 111-117.
  23. Kanono Thabane., et al. “Exploring factors associated with breast cancer screening among women aged 15-49 years in Lesotho”. Panafrican Medical Journal 38 (2021).
  24. KM OM., et al. “Expenses incurred by patients obtaining free breast cancer care in Haiti: a pilot study”. Science Direct (2015) 747-755.
  25. Knaul Felicia Marie., et al. “Breast Cancer in Mexico: An Urgent Priority”. Reproductive Health Issues 16.32 (2008): 113-123.
  26. The Cancer Atlas. “The Cancer Atlas”. The Cancer Atlas (2021).
  27. Li S., et al. “Overall breast cancer treatment costs by stage: a systematic review”. PLOS ONE (2018).
  28. M Gueye., et al. “Profile of a black woman in Senegal with breast cancer”. Tropical Health Medicine 26.2 (2016): 165-169.
  29. Madiéye Gueye., et al. “Breast cancer in women younger than 35 years : features and outcomes in the breast unit at Aristide le Dantec Teaching Hospital, Dakar”. Tropical Medicine and Health 26.4 (2016): 377-381.
  30. María CG., et al. “Breast Cancer Care Costs in Mexico: Analysis of Two Insurance Coverage Scenarios”. Ecancermedicalscience 9 (2015).
  31. Mathias L., et al. “Cost of breast cancer in Sweden in 2002”. Eur J Health Econ (2007): 5-15.
  32. Matt Swayne LJ. Cancer costs more than 156 billion dollars in the United States, and drugs represent a major expense. (Penn state) (2021).
  33. Omolola Salako AA. “Using the Cancer Information System to Fight Breast Cancer in Lagos, Nigeria”. Panafrican Medical Journal 24.323 (2016): 24-326.
  34. Sarré B., et al. “Epidemiologist, therapeutic and prognostic aspects of breast cancer: about 473 cases collected at the Hôpital Principal de Dakar”. Dakar Med 51.2 (2006): 92-96.
  35. Sartorius K., et al. “The Future Cost of Cancer in South Africa: An Interdisciplinary Cost Management Strategy”. South African Medical Journal 106.10 (2016): 949-950.
  36. Shehnaz K Hussein. “Influence of education level on breast cancer risk and survival in Sweden between 1990 and 2004”. International Journal of cancer 122.1 (2007): 165-169.
  37. Shiva Ram Khatiwoda., et al. Estimating the Direct Cost of Cancer in Nepal: A Cross-sectional Study in a Tertiary Cancer Hospital”. Front Public Health (2019).
  38. Soares IS., et al. “The public-private mix in the Brazalian Health System: Financing, delivery and utilization of health services”. SCI ELO BRAZIL (2008): 1431-1440.
  39. Sri Yusnita irda Sari DD., et al. “Low knowledge and negative perception of breast cancer risks among high school girls”. Althea Medical Journal 6.3 (2019).
  40. Teich NC., et al. “Retrospective analysis of the costs of breast cancer patients treated in a Brazilian outpatient cancer centre”. Journal of Clinical Oncology (2010).
  41. Teshale Mulatu Dibisa., et al. “The practice of breast cancer screening and its associated factors among women in the Kersa district, eastern Ethiopia”. Panafrican Medical Journal 33.144 (2019): 33-144.
  42. Thi Tuyet Mai Kieu., et al. “Direct non-medical and indirect costs of diabetes and its associated complications in Vietnam: an estimate using national health insurance claims from a cross-sectional survey”. BMJ Open (2020).
  43. Umesh MM. “Scaling up radiation therapy for cervical cancer”. The lancet Oncology (2019): 888-889.
  44. Van Minh Hoang., et al. “Household financial burden and poverty impacts of cancer treatment in Vietnam”. Biomed Res Int (2017).
  45. Will BP., et al. “Estimates of the lifetime costs of breast cancer treatment in Canada”. Eur J Cancer 36.6 (2000): 724-735.
  46. Yohana EA., et al. “Availability and affordability of anti-cancer drugs at the Ocean Road Cancer Institute in Dar Es Salaam, Tanzania”. Journal of Public Health of East Africa 8.1 (2011): 52-57.

Foot Notes

  1. Institute of Environmental Sciences of the Cheikh Anta Diop University of Dakar.
  2. Statistical Packdge for Socail Sciences.
  3. https://myfin.fr/convertisseur-devise/xof-usd/10024